Pharmacokinetic Drug–Drug Interaction Studies Between Trilaciclib and Midazolam, Metformin, Rifampin, Itraconazole, and Topotecan in Healthy Volunteers and Patients with Extensive-Stage Small-Cell Lung Cancer

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1179-1918

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Pharmacokinetic Drug–Drug Interaction Studies Between Trilaciclib and Midazolam, Metformin, Rifampin, Itraconazole, and Topotecan in Healthy Volunteers and Patients with Extensive-Stage Small-Cell Lung Cancer ; volume:42 ; number:8 ; day:16 ; month:7 ; year:2022 ; pages:679-692 ; date:8.2022
Clinical drug investigation ; 42, Heft 8 (16.7.2022), 679-692, 8.2022

Creator: Li, Chao
Horton, Janet K.
Sale, Mark
Curd, Laura
Goti, Vineet
Tao, Wenli
Beelen, Andrew

Contributor: SpringerLink (Online service)

DOI: 10.1007/s40261-022-01179-x

URN: urn:nbn:de:101:1-2022101517045917838281

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:32 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Li, Chao
Horton, Janet K.
Sale, Mark
Curd, Laura
Goti, Vineet
Tao, Wenli
Beelen, Andrew
SpringerLink (Online service)

Other Objects (12)

Midazolam Microdosing and Population Pharmacokinetic Modelling to Assess CYP3A Drug-Drug Interactions in Early Clinical Development

Delta-9-Tetrahydrocannabinol and Cannabidiol Drug-Drug Interactions

Evaluating drug-drug interaction information in NDF-RT and DrugBank

Drug−Drug Interactions Involving Intestinal and Hepatic CYP1A Enzymes

Drug–Drug Interactions Between Direct-Acting Antivirals and Psychoactive Medications

Pharmacokinetics and Drug–Drug Interactions of Long-Acting Intramuscular Cabotegravir and Rilpivirine

Modelling and simulation techniques to investigate pharmacokinetics, pharmacodynamics, and drug-drug interactions

Multi-view feature representation and fusion for drug-drug interactions prediction

Drug–Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies

Targeting continuity of care and polypharmacy to reduce drug–drug interaction

Pharmacotherapy, drug-drug interactions and potentially inappropriate medication in depressive disorders

A Review of Daclatasvir Drug–Drug Interactions

Midazolam Microdosing and Population Pharmacokinetic Modelling to Assess CYP3A Drug-Drug Interactions in Early Clinical Development

Delta-9-Tetrahydrocannabinol and Cannabidiol Drug-Drug Interactions

Evaluating drug-drug interaction information in NDF-RT and DrugBank

Drug−Drug Interactions Involving Intestinal and Hepatic CYP1A Enzymes

Drug–Drug Interactions Between Direct-Acting Antivirals and Psychoactive Medications

Pharmacokinetics and Drug–Drug Interactions of Long-Acting Intramuscular Cabotegravir and Rilpivirine

Modelling and simulation techniques to investigate pharmacokinetics, pharmacodynamics, and drug-drug interactions

Multi-view feature representation and fusion for drug-drug interactions prediction

Drug–Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies

Targeting continuity of care and polypharmacy to reduce drug–drug interaction

Pharmacotherapy, drug-drug interactions and potentially inappropriate medication in depressive disorders

A Review of Daclatasvir Drug–Drug Interactions

Midazolam Microdosing and Population Pharmacokinetic Modelling to Assess CYP3A Drug-Drug Interactions in Early Clinical Development

Delta-9-Tetrahydrocannabinol and Cannabidiol Drug-Drug Interactions

Evaluating drug-drug interaction information in NDF-RT and DrugBank

Drug−Drug Interactions Involving Intestinal and Hepatic CYP1A Enzymes

Drug–Drug Interactions Between Direct-Acting Antivirals and Psychoactive Medications

Pharmacokinetics and Drug–Drug Interactions of Long-Acting Intramuscular Cabotegravir and Rilpivirine

Modelling and simulation techniques to investigate pharmacokinetics, pharmacodynamics, and drug-drug interactions

Multi-view feature representation and fusion for drug-drug interactions prediction

Drug–Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies

Targeting continuity of care and polypharmacy to reduce drug–drug interaction

Pharmacotherapy, drug-drug interactions and potentially inappropriate medication in depressive disorders

A Review of Daclatasvir Drug–Drug Interactions

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Pharmacokinetic Drug–Drug Interaction Studies Between Trilaciclib and Midazolam, Metformin, Rifampin, Itraconazole, and Topotecan in Healthy Volunteers and Patients with Extensive-Stage Small-Cell Lung Cancer

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Midazolam Microdosing and Population Pharmacokinetic Modelling to Assess CYP3A Drug-Drug Interactions in Early Clinical Development

Delta-9-Tetrahydrocannabinol and Cannabidiol Drug-Drug Interactions

Evaluating drug-drug interaction information in NDF-RT and DrugBank

Drug−Drug Interactions Involving Intestinal and Hepatic CYP1A Enzymes

Drug–Drug Interactions Between Direct-Acting Antivirals and Psychoactive Medications

Pharmacokinetics and Drug–Drug Interactions of Long-Acting Intramuscular Cabotegravir and Rilpivirine

Modelling and simulation techniques to investigate pharmacokinetics, pharmacodynamics, and drug-drug interactions

Multi-view feature representation and fusion for drug-drug interactions prediction

Drug–Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies

Targeting continuity of care and polypharmacy to reduce drug–drug interaction

Pharmacotherapy, drug-drug interactions and potentially inappropriate medication in depressive disorders

A Review of Daclatasvir Drug–Drug Interactions

Midazolam Microdosing and Population Pharmacokinetic Modelling to Assess CYP3A Drug-Drug Interactions in Early Clinical Development

Delta-9-Tetrahydrocannabinol and Cannabidiol Drug-Drug Interactions

Evaluating drug-drug interaction information in NDF-RT and DrugBank

Drug−Drug Interactions Involving Intestinal and Hepatic CYP1A Enzymes

Drug–Drug Interactions Between Direct-Acting Antivirals and Psychoactive Medications

Pharmacokinetics and Drug–Drug Interactions of Long-Acting Intramuscular Cabotegravir and Rilpivirine

Modelling and simulation techniques to investigate pharmacokinetics, pharmacodynamics, and drug-drug interactions

Multi-view feature representation and fusion for drug-drug interactions prediction

Drug–Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies

Targeting continuity of care and polypharmacy to reduce drug–drug interaction

Pharmacotherapy, drug-drug interactions and potentially inappropriate medication in depressive disorders

A Review of Daclatasvir Drug–Drug Interactions

Midazolam Microdosing and Population Pharmacokinetic Modelling to Assess CYP3A Drug-Drug Interactions in Early Clinical Development

Delta-9-Tetrahydrocannabinol and Cannabidiol Drug-Drug Interactions

Evaluating drug-drug interaction information in NDF-RT and DrugBank

Drug−Drug Interactions Involving Intestinal and Hepatic CYP1A Enzymes

Drug–Drug Interactions Between Direct-Acting Antivirals and Psychoactive Medications

Pharmacokinetics and Drug–Drug Interactions of Long-Acting Intramuscular Cabotegravir and Rilpivirine

Modelling and simulation techniques to investigate pharmacokinetics, pharmacodynamics, and drug-drug interactions

Multi-view feature representation and fusion for drug-drug interactions prediction

Drug–Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies

Targeting continuity of care and polypharmacy to reduce drug–drug interaction

Pharmacotherapy, drug-drug interactions and potentially inappropriate medication in depressive disorders

A Review of Daclatasvir Drug–Drug Interactions

Related objects

Reset password